4-(2,3-二氢-1,4-苯并二氧-6-基)-4-氧丁酸 | 54557-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2,3-二氢-1,4-苯并二氧-6-基)-4-氧丁酸
• 英文名称: 3-(6-<1,4>benzodioxanylcarbonyl)propionic acid
• 英文别名: 4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4-oxo-butyric acid；4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-4-oxo-buttersaeure；4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-oxobutanoic acid
• CAS: 54557-81-2
• 化学式: C₁₂H₁₂O₅
• mdl: MFCD00168683
• 分子量: 236.224
• InChiKey: LMDXEMFSAHAGGP-UHFFFAOYSA-N

物化性质

• 熔点：
  138 °C
• 沸点：
  475.6±45.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2932999099

SDS

Name:	4-(2 3-Dihydro-1 4-benzodioxin-6-yl)-4-oxobutanoic acid 97% Material Safety Data Sheet
Synonym:	3-(3,4-Ethylenedioxybenzoyl)propionic aci
CAS:	54557-81-2

Section 1 - Chemical Product MSDS Name:4-(2 3-Dihydro-1 4-benzodioxin-6-yl)-4-oxobutanoic acid 97% Material Safety Data Sheet
Synonym:3-(3,4-Ethylenedioxybenzoyl)propionic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
54557-81-2	4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-4	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 54557-81-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 137 - 139 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H12O5
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 54557-81-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-4-oxobutanoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 54557-81-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 54557-81-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 54557-81-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2,3-二氢-1,4-苯并二氧-6-基)-4-氧丁酸 在 三氟甲磺酸 、 一水合肼 、 sodium hydroxide 作用下， 反应 10.0h， 生成 2,3,8,9-tetrahydronaphtho[2,3-b][1,4]dioxin-6(7H)-one
  参考文献：
  名称：

  用二乙基氨基三氟化硫和（三氟甲基）三甲基硅烷对甲硅烷基醚和β-萘酚进行亲电三氟甲基硫醇化

  摘要：

  利用二乙基氨基三氟化硫（DAST）和（三氟甲基）三甲基硅烷（CF 3 TMS）的组合作为合成三α-三氟甲硫基羰基化合物的亲电三氟甲硫基化合物，已经完成了甲硅烷基醚和β-萘酚的高效且通用的三氟甲硫基化反应。β萘酚的收率很高。该方法的重要特征包括宽泛的官能团耐受性和使用现成的DAST / CF 3 TMS。通过α-三氟甲基硫醇化（+）-4-胆甾烯-3-酮和萘醌的合成证明了该方法的潜力。

  DOI：

  10.1002/adsc.201800366
• 作为产物：
  描述：

  4-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-4-oxo-butyric acid ethyl ester 在 sodium hydroxide 作用下， 反应 2.0h， 以90%的产率得到4-(2,3-二氢-1,4-苯并二氧-6-基)-4-氧丁酸
  参考文献：
  名称：

  Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system

  摘要：

  A series of substituted derivatives containing the 1,4-benzodioxine or pyrrole nucleus are described. All the newly synthesized compounds were examined for their in vitro and in vivo anti-inflammatory activity. Several derivatives, including (S)-2, 14 and 17, showed more anti-inflammatory activity in vivo in these assays (rat paw oedema induced by carrageenan) than the known classical anti-inflammatory agent ibuprofen, whereas other compounds like 1 were equipotent to ibuprofen. Compound 17 was the most outstanding derivative because of its remarkable in vivo anti-inflammatory activity. In this paper, we examine and discuss the structure-activity relationships and anti-inflammatory activities of these compounds. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.04.050

文献信息

• NOVEL INHIBITORS
  申请人：Heiser Ulrich

  公开号：US20110092501A1

  公开（公告）日：2011-04-21

  The invention relates to novel pyrrolidine derivatives of formula (I): wherein R 1 , R 2 and R 3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  本发明涉及新颖的吡咯烷衍生物，其具有如下公式(I)：其中R1、R2和R3如本文所述定义，作为谷氨酰胺环化酶（QC，EC 2.3.2.5）的抑制剂。谷氨酰胺环化酶催化N末端谷氨酰胺残基形成焦谷氨酸（5-氧代脯氨酸，pGlu*）的分子内环化，并释放氨，以及催化N末端谷氨酸残基形成焦谷氨酸的分子内环化，并释放水。
• Novel Acyl Coenzyme A: Diacylglycerol Acyltransferase 1 Inhibitors-Synthesis and Biological Activities of N-(Substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides
  作者：Yoshihisa Nakada、Masaki Ogino、Kouhei Asano、Kazuko Aoki、Hiroshi Miki、Toshihiro Yamamoto、Koki Kato、Minori Masago、Norikazu Tamura、Mitsuyuki Shimada

  DOI：10.1248/cpb.58.673

  日期：——

  discover new small molecule diacylglycerol acyltransferase (DGAT)-1 inhibitors, screening of our in-house chemical library was carried out using recombinant human DGAT-1 enzyme. From this library, the lead compound 1a was identified as a new class of DGAT-1 inhibitor. A series of novel N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides 2 was designed from 1a, synthesized and evaluated

  在发现新的小分子二酰基甘油酰基转移酶（DGAT）-1抑制剂的程序中，使用重组人DGAT-1酶筛选了我们内部的化学文库。从该文库中，先导化合物1a被鉴定为一类新的DGAT-1抑制剂。从1a设计了一系列新型的N-（取代的杂芳基）-4-（取代的苯基）-4-氧代丁酰胺2，合成并评估了其对DGAT-1酶的抑制活性。在这些化合物中，发现N-（5-苄基-4-苯基-1,3-噻唑-2-基）-4-（4,5-二乙氧基-2-甲基苯基）-4-氧代丁酰胺9显示出有效的抑制作用。活性和良好的酶选择性。用3 mg / kg高脂饮食混合物在KKA（y）小鼠中施用4周后，有9只小鼠的体重增加和白色脂肪组织重量减少，而不会影响总食物摄入量。
• Pyridazines. VI. Some 6-substituted 3(2<i>H</i>)pyridazinones
  作者：Edgar A. Steck、R. Pauline Brundage、Lynn T. Fletcher

  DOI：10.1002/jhet.5570110518

  日期：1974.10

  A series of 6-substituted 3(2H)pyridazinones was prepared. The 6-substituent was either aromatic of heter-aromatic in structure. A few basically-substituted representatives were also made.

  制备了一系列6-取代的3（2 H）吡啶并酮。6-取代基在结构上是杂芳族的芳族化合物。还提出了一些基本被取代的代表。
• [EN] MACROLIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES A BASE DE MACROLIDES
  申请人：GLAXO GROUP LTD

  公开号：WO2002050091A1

  公开（公告）日：2002-06-27

  The present invention relates to 11,12 η lactone ketolides of formula (I) wherein R, R?1, R2, R3¿ are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式（I）的11,12-η内酯酮类化合物，其中R，R?1，R2，R3¿如本文所定义，并且其药学上可接受的盐和溶剂合物，以及其制备过程和在治疗或预防人类或动物体内的全身性或局部细菌感染中的应用。
• [EN] HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE GLUTAMINYLE CYCLASE
  申请人：PROBIODRUG AG

  公开号：WO2011029920A1

  公开（公告）日：2011-03-17

  The invention relates to novel pyrrolidine derivatives of formula (I), wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  本发明涉及一种新的吡咯烷衍生物，其化学式为（I），其中R1、R2和R3如本文所定义，在抑制谷氨酰环化酶（QC，EC 2.3.2.5）方面具有作用。QC催化N-末端谷氨酰残基的分子内环化成为吡咯谷氨酸（5-氧代脯氨酰基，pGlu*），同时释放氨，并将N-末端谷氨酸残基的分子内环化成为吡咯谷氨酸，并释放水。